Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 26, 2006

Adenosine Therapeutics Awarded Approximately $1.8M from NIAID

  • Adenosine Therapeutics was awarded four new grants totaling approximately $1,887,634. These grants will help further evaluate new therapeutic approaches for the treatment of asthma, sepsis, and arthritis.

    The NIAID funded the grants: a Phase I STTR-AT grant of $861,737 to further expand research on the use of apadenoson, the company's selective A2A agonist that is in Phase III testing as a heart imaging agent for the treatment of sepsis; a Phase II SBIR grant totaling $755,496 to identify an A2BR antagonist as a therapeutic candidate for the treatment of asthma; a Phase I STTR grant for $132,798 to further expand its preclinical research on the use of agents that activate the adenosine A2A receptor subtypes for the treatment of S. aureus sepsis; and a Phase I STTR of $137,603 to further expand its clinical research on the use of agents that activate the adenosine A2A receptor subtypes for the treatment of arthritis.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »